Firstly, it is highly expressed in malignant tissues relative to normal tissue counterparts (Figure 3), and FRα expression is no longer polarized to a particular tissue area.34 Secondly, higher levels of FRα expression correlate with disease stage as well as recurrence in a variety of solid tumors, including ovarian cancer, triple negative breast cancer, and lung cancer.35–37 This highlights the potential prognostic role for FRα and further emphasizes its promise as a target in advanced disease. This evidence concerns the gene FOLR1 and lung carcinoma.